Aptamer Sciences Inc Logo

Aptamer Sciences Inc

Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.

291650 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로228번길 15 3동 301호(삼평동, 판교세븐벤처밸리1), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative aptamer-based technologies for therapeutics and diagnostics. The company leverages its proprietary integrated platforms to address unmet medical needs, primarily in oncology. Its therapeutic pipeline is centered on the ApDC™ (Aptamer-Drug Conjugate) platform, with lead candidate AST-201 advancing to clinical trials for treating GPC3-positive solid tumors like liver cancer. In the diagnostics segment, the company has developed and commercialized the AptoDetect™ platform, which includes AptoDetect™-Lung, an aptamer-based diagnostic kit for assessing lung cancer risk. Aptamer Sciences focuses on advancing its pipeline and forming strategic partnerships to commercialize its novel aptamer technologies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Aptamer Sciences Inc and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 84.4 KB
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.9 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.4 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 40.2 KB
2025-09-09 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 5.9 KB
2025-09-09 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 77.9 KB
2025-09-08 00:00
M&A Activity
경영권변경등에관한계약체결
Korean 15.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.3 KB

Automate Your Workflow. Get a real-time feed of all Aptamer Sciences Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Aptamer Sciences Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.